Breaking News, Collaborations & Alliances

Emergent BioSolutions, MorphoSys Enter Prostate Cancer Drug Pact

Will initiate a Phase I trial of ES414 within the next six months

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions Inc. and MorphoSys AG have entered an agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer. Emergent will receive an upfront payment of $20 million and milestone payments of as much as $163 million for the successful development of ES414 in several indications.   Emergent developed ES414 using its ADAPTIR modular protein technology platform. Preclinical studies have shown that ES414 redire...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters